Maravai Lifesciences Holdings's major customers
Nacalai USA accounted for 21% of Maravai Lifesciences Holdings's revenue in FY 2024, about the same as 19% a year earlier.
Get an email when Maravai Lifesciences Holdings's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Major customers of Maravai Lifesciences Holdings
Customers that Maravai Lifesciences Holdings named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Nacalai USA | 21% | from 19% | 2 years | FY 2024 · filed 26 Feb 2026 |
Formerly disclosed
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Bio N TechBNTX | 35% | last FY 2022 | 3 years | FY 2022 · filed 18 Mar 2025 |
| PfizerPFE | 26% | last FY 2022 | 3 years | FY 2022 · filed 18 Mar 2025 |
| Cure Vac | 15% | last FY 2021 | 1 year | FY 2021 · filed 29 Feb 2024 |
| Thermo Fisher ScientificTMO | 10% | last FY 2019 | 1 year | FY 2019 · filed 1 Mar 2022 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API